274 results about "Hydrobromic acid" patented technology

The invention relates to the technical field of organic synthesis, and discloses a preparation method of bromo-pyrrole nitrile. The method comprises the following steps: (1) mixing p-chlorophenylglycine, acetonitrile, trifluoroacetic acid and a catalyst, then dropwise adding acyl chloride and carrying out acylation reaction, and after the reaction is completed, purging with an inert gas; (2) under the inert gas, mixing the mixture obtained in the step (1) with inorganic salt, then dropwise adding 2-chloroacrylonitrile, carrying out cyclization reaction, and separating a liquid phase from the obtained mixture; and (3) under the inert gas, mixing the liquid phase obtained in the step (2), hydrobromic acid and hydrogen peroxide, carrying out a bromination reaction, then extracting with acetonitrile to obtain an acetonitrile layer, then removing the acetonitrile, and then carrying out cooling crystallization to obtain the bromo-pyrrolenitrile. According to the technical scheme, the reaction yield is high, different solvents do not need to be frequently replaced, and the solvents can be recycled.

The invention particularly relates to a preparation method of a high-fluidity vortioxetine hydrobromide alpha crystal form. According to the technical scheme, vortioxetine hydrobromide is dissolved in an organic solvent with the volume being 5-10 times that of the vortioxetine hydrobromide, insoluble substances are filtered out, and polyvinylpyrrolidone with the mass being 1-2.5 times that of the vortioxetine hydrobromide is added into filtrate; and feeding the solution into pre-cooled purified water containing seed crystals for crystallization, filtering, and drying to constant weight. The obtained vortioxetine hydrobromide is in an alpha crystal form, is spherical, has the particle size of less than 15 microns and the specific surface area of more than 1600 m < 2 > / kg, and is high in dissolution rate, good in fluidity, high in yield and easy to industrialize.

The present application provides a method for extracting lithium from salt lakes. The method comprises the following steps: (1) subjecting concentrated brine to ammonia vapor magnesium precipitation treatment to obtain a magnesium-removed filtrate and filter residue; (2) mixing the filter residue with hydrobromic acid, adjusting the pH to precipitate boric acid, and performing solid-liquid separation to obtain a filtrate and boric acid; (3) evaporating and concentrating the filtrate obtained in step (2), performing aeration treatment after drying treatment, and performing water immersion separation treatment to obtain a lithium-rich solution and magnesium oxide; (4) mixing the lithium-rich solution and lithium carbonate to perform a solid-phase transformation reaction, and filtering to obtain a purified lithium salt solution and calcium carbonate. The method of the present application can separate boron, magnesium, and calcium-lithium in one step, and further calcium removal can separate calcium and lithium, which is beneficial to obtaining high-purity lithium carbonate and reducing lithium loss caused by the adsorption of lithium by magnesium hydroxide colloid.

The invention relates to the technical field of biology, in particular to an inducer, a reagent combination and application of the inducer in preparation of anisodamine. The inducing agent comprises silver nitrate, acetylsalicylic acid and methyl jasmonate, the components of the inducing agent cooperate with one another, compatibility is high, synergistic interaction can be achieved, and the efficiency of the inducing agent for rapidly converting hyoscyamine into anisodamine is further improved. According to the invention, a suspension cell culture technology is adopted, and an optimized callus culture medium, a precursor substance hyoscyamine and an inducer are combined, so that compared with an initial material anisodamine tanguticum used by an existing anisodamine hydrobromide raw material medicine, the anisodamine hydrobromide raw material medicine has the advantages of short growth cycle, stable content and components, environmental protection and no damage to natural resources; the invention provides a new approach for obtaining a starting material for the production of an anisodamine hydrobromide bulk drug, and is suitable for popularization and application.

The invention belongs to the technical field of flame retardants, and particularly relates to a melamine hydrobromide flame retardant and a preparation method thereof. The flame retardant disclosed by the invention has a core-shell structure, the core is hydroxylated melamine hydrobromide subjected to surface modification by a silane coupling agent, and the shell is melamine resin synergistically enhanced by ammonium polyphosphate and oxidized cellulose nanofibrils; through silanization treatment, core-shell interface combination is enhanced, and space-time synergy of gas phase and condensed phase flame retardance is achieved through a composite shell; the obtained flame retardant is high in thermal stability in a polymer matrix, the limit oxygen index of a composite material can be remarkably increased after the flame retardant is added, and the flame retardant has a wide application prospect in the field of flame retardance of high polymer materials through a UL-94 V-0 grade test.

The invention discloses preparation and application of an amido-functionalized polyionic liquid catalyst, vinyl imidazole hydrobromide and N-(4-vinyl) benzyl diethylamine are used as monomers, N, N '-methylene bisacrylamide is used as a cross-linking agent, and the amido-functionalized polyionic liquid catalyst is prepared through a free radical copolymerization method. The imidazole / amido functionalized cross-linked PILs with multiple active sites are prepared by one-step synthesis through a hydrothermal polymerization method. The catalyst has catalytic active sites of amido, imidazolyl and Br, so that the catalyst can efficiently catalyze the cycloaddition reaction of CO2 and epoxide at 80 DEG C and normal pressure in the absence of a solvent and a co-catalyst.

This invention relates to the field of chemical synthesis technology and discloses a method for preparing 2,5-furandicarboxylic acid from fructose, comprising the following steps: preparing reaction system A containing fructose, an organic bromide, a solid acid catalyst, and water; performing a dehydration reaction to separate the solid acid catalyst and obtain a fructose dehydration reaction solution; preparing reaction system B containing the fructose dehydration reaction solution, a co-oxidant, an oxidation catalyst, and acetic acid; performing an oxidation reaction under an oxidizing gas atmosphere; separating the product to obtain 2,5-furandicarboxylic acid. This invention utilizes a co-oxidant, which can reduce the requirement for fructose concentration in the one-pot preparation of 2,5-furandicarboxylic acid while ensuring the yield and purity of FDCA, thereby improving production efficiency. Furthermore, it reduces or even eliminates the use of hydrobromic acid in the oxidation reaction, thus reducing corrosion to equipment.

The invention discloses a method for detecting an N-nitroso compound in vortioxetine hydrobromide, and the N-nitroso compound is 2, 2 '-(nitroso amino) bis-acetonitrile. According to the method, a high performance liquid chromatography is adopted, an octadecyl silane bonded silica gel filler chromatographic column and an ultraviolet detector are adopted, a mobile phase A is 0.05% phosphoric acid aqueous solution, a mobile phase B is methanol, and gradient elution is adopted. The method has good specificity and sensitivity.

The invention relates to the technical field of cable preparation, and provides a high-strength low-voltage power cable, which comprises a cable core, and an aluminum-plastic composite wrapping tape, a mica wrapping tape and a sheath layer which sequentially wrap the cable core from inside to outside, the sheath layer comprises the following substances: an ethylene-vinyl acetate copolymer, linear low-density polyethylene resin, a modified flame retardant, montmorillonite, a light stabilizer, a lubricant, an antioxidant and polyethylene grafted maleic anhydride; wherein a preparation process of the modified flame retardant comprises the following steps: mixing melamine hydrobromide, absolute ethyl alcohol and deionized water, uniformly stirring, raising the temperature, adding a composite additive, stirring to react, cooling to room temperature after the reaction is finished, and drying to obtain the modified flame retardant. The preparation method has the beneficial effects that the surface of the melamine hydrobromide is coated, so that the antagonism between the melamine hydrobromide and the light stabilizer is reduced; in addition, long-chain alkyl groups and flame-retardant groups contained in the flame-retardant polyester resin further improve the flame-retardant effect and the mechanical property of the material.

The present application relates to a trace neodymium doped phenethylamine lead bromide monocrystal capable of simultaneously enhancing light yield and shortening decay time and application thereof, which solves the technical problem that the prior art is difficult to simultaneously improve light yield and shorten luminescence decay time. The trace neodymium doped phenethylamine lead bromide monocrystal capable of simultaneously enhancing light yield and shortening decay time is prepared by the following steps: 1) weighing; phenethylamine hydrobromide, lead bromide and neodymium bromide are weighed and placed in a glass bottle; the molar ratio of the phenethylamine hydrobromide, lead bromide and neodymium bromide is 2:1:(0.02-0.05); 2) obtaining a precursor solution; N,N-dimethylformamide is added to the glass bottle, heated and stirred until completely dissolved to obtain a precursor solution; 3) obtaining a crystal; the precursor solution is filtered and placed in a glass beaker for crystallization to obtain a neodymium doped phenethylamine lead bromide monocrystal; through adjustment of the crystal band structure by neodymium, the radiation recombination rate is improved.

The invention belongs to the technical field of cough relieving and phlegm eliminating medicines, and particularly relates to compound dextromethorphan hydrobromide syrup and a preparation method thereof. On the basis that the total volume of the compound dextromethorphan hydrobromide syrup is 1000L, the compound dextromethorphan hydrobromide syrup provided by the invention is prepared from the following components: 3000g of dextromethorphan hydrobromide, 20kg of guaiacol glyceryl ether, 650kg of cane sugar, 100L of 1, 2-propylene glycol, 2000g of benzoic acid, 200g of sodium benzoate, 100g of menthol, 4000mL of essence, 14000mL of ethanol, 2000mL of caramel pigment and the balance of purified water. The compound dextromethorphan hydrobromide syrup provided by the invention takes benzoic acid as a main preservative and is matched with sodium benzoate; meanwhile, the dosage ratio of all the components in the syrup is optimized, the obtained compound dextromethorphan hydrobromide syrup is good in preservative effect, and adverse reactions are reduced.

The present invention provides a pharmaceutically acceptable salt and crystal form of a KIF18A inhibitor, and a preparation method therefor and a use thereof. The pharmaceutically acceptable salt is selected from one or more of a sodium salt, a potassium salt, a hydrochloride, a p-toluenesulfonate, a maleate, a methanesulfonate, an ethanesulfonate, and a hydrobromide of a compound represented by formula (I). The present invention provides the pharmaceutically acceptable salt of the compound represented by formula (I) and a crystal of the salt, which exhibit excellent hygroscopicity, solubility, and / or stability, and are suitable for pharmaceutical use.

The present disclosure relates to administering in a human patient a combination of: 1) about 100 to 110 mg, about 104 to 106 mg, or about 105 mg or less of bupropion hydrochloride or a molar equivalent amount of bupropion in a free base form or another salt form; and 2) a free base form or another salt form of dextromethorphan hydrobromide or a molar equivalent amount of dextromethorphan or a molar equivalent amount of dextromethorphan or another salt form of about 40-50 mg, about 44-46 mg, or about 45 mg or less for use in the treatment of neurological and psychiatric conditions, such as agitation associated with Alzheimer's disease, and / or reducing recurrence of agitation in Alzheimer's disease.

The invention provides a preparation method of N, N-diisopropylethylamine based on a liquid-phase compression synthesis process, which comprises the following steps: mixing ethanol with hydrobromic acid with specified concentration, and carrying out reactive distillation treatment in the presence of a phase transfer catalyst to generate bromoethane; p-bromoethane and diisopropylamine are subjected to a liquid phase addition and compression combination reaction, and a reaction mixture is obtained; and sequentially neutralizing, distilling, condensing and filtering the reaction mixture to obtain the N, N-diisopropylethylamine, so as to solve the problems that the existing preparation method of the N, N-diisopropylethylamine is high in energy consumption, high in operation risk, large in pollutant discharge amount, low in by-product resource utilization rate, low in cost and the like. The safety is poor; the energy efficiency is low; and by-products cannot be recycled.

The application provides an Ag etching solution, a preparation method and application thereof. The Ag etching solution comprises the following components in a weight ratio: 40-80 parts of inorganic acid; 10-50 parts of organic acid; 0.05-1.5 parts of corrosion inhibitor; 0.1-2 parts of chelating agent; 1-7.5 parts of buffer; and 30-50 parts of ultrapure water. The application further discloses a preparation method of the Ag etching solution and application thereof in the field of etching ITO-Ag-ITO composite layers. The inorganic acid is selected from one or more of phosphoric acid, sulfuric acid, carbonic acid, boric acid, hydrobromic acid, iodic acid, hypoiodous acid, hydrofluoric acid and nitric acid. The inorganic acid is preferably phosphoric acid and nitric acid. The Ag etching solution has a stable etching rate for ITO-Ag-ITO, and is not damaged to the insulating layer and photoresist, and can be used in the OLED pixel electrode manufacturing process, and the Ag layer is not provided with burrs and is not shrunk after etching.

The present invention relates to the technical field of organic chemistry, and discloses a preparation method of 9-phenanthrene formic acid, wherein the preparation method comprises the following steps: using phenanthrene as a main raw material, iron bromide or zinc bromide as a catalyst, reacting with hydrobromic acid and hydrogen peroxide at 20 to 50 ° C to generate 9-bromophenanthrene, 9-bromophenanthrene reacts with cyanide under a catalyst to generate 9-nitrile phenanthrene, and then hydrolyzing under alkaline conditions to obtain 9-phenanthrene formic acid. The present invention uses cheap and readily available raw materials such as phenanthrene, hydrobromic acid, hydrogen peroxide and sodium cyanide to prepare 9-phenanthrene formic acid, with low production cost, high conversion rate, good product quality, mild reaction conditions, low equipment requirements, and can be used for large-scale industrial preparation of 9-phenanthrene formic acid.

The application discloses a method for industrial production of sulindac. The method comprises the following steps: condensation reaction of compound 1 (5-fluoro-2-1-(4-methylthio benzyl) indene) and glyoxylic acid under catalysis of an organic base (benzyl trimethyl ammonium hydroxide) to generate compound 2, isomerization reaction of the compound 2 under hydrobromic acid-acetic acid solution to generate compound 3, which greatly improves reaction conversion rate and yield, reduces three waste problems, and finally obtains compound 4 (sulindac crude product) through oxidation of the obtained compound 3 by hydrogen peroxide, and high-purity sulindac is obtained through recrystallization of the crude product by isopropyl alcohol. The raw materials and reagents used in the preparation process of the sulindac are relatively cheap and low in cost, the whole preparation process is mild in reaction condition, simple and safe in operation, and convenient for industrial production.

Disclosed in the present invention is a method for directly preparing a phenol and an aldehyde or a ketone from an alkyl aromatic hydrocarbon as a raw material on the basis of a selective carbon-carbon bond oxidative cleavage reaction. The method is carried out on the basis of the following steps: mixing an alkyl aromatic hydrocarbon as represented by general formula (I) with a photocatalyst, hydrobromic acid, and an organic solvent and enabling the mixture to react under the conditions of oxygen as an oxidant and light irradiation to simultaneously prepare a phenol compound as represented by general formula (II) and a ketone or aldehyde compound as represented by general formula (III). In the present invention, bulk alkyl aromatic hydrocarbons are used as raw materials for reaction to produce phenol, aldehyde, and ketone organic chemical raw materials. Compared with traditional synthesis methods, the present invention has many advantages such as inexpensive and readily available catalysts, mild reaction conditions, simple operation, good selectivity, and high safety, is suitable for large-scale synthesis of phenols, p-cresol, cyclohexanone, etc., and exhibits wide application prospects.

The invention provides a rapid and high-precision determination method for reduction-state Os isotope. The method comprises the following steps: selecting a sample to be detected and carrying out ultrafine crushing; weighing the ground to-be-detected sample, and sealing and dissolving the sample; taking out the dissolved to-be-detected sample, and adding isometric hydrobromic acid to convert oxidation state Os into reduction state Os; carrying out acid removal and constant volume on the reduced-state Os solution; establishing a cup structure for static determination of the Os isotope, and performing MC-ICP-MS determination of the reduction state Os isotope according to the cup structure. According to the present invention, the dissolved to-be-tested sample is creatively taken out, and the isometric hydrobromic acid is added so as to convert the oxidation state Os into the reduction state Os, such that the memory effect can be substantially reduced, the efficiency can be improved, the research cost and the research time can be reduced when the MC-ICP-MS is adopted to rapidly and precisely measure the Os isotope, and the method is suitable for the mass sample test.

LSD derivative compounds and polymorphs thereof, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula I' selected from,,,, or combination thereof, wherein the acid is selected from formic acid, malic acid (D and L), pyroglutamic acid (D and L), citric acid, phosphoric acid, aspartic acid (D and L), methane sulfonic acid, ethane sulfonic acid, benzenesulfonic acid, sulfuric acid, glutamic acid (D and L), ascorbic acid (D and L), isoascorbic acid (D and L), hydrochloric acid, hydrobromic acid, ethane sulfonic acid, tartaric acid (D and L), or meso-tartaric acid.

The application discloses a preparation method of o-bromoanisole. The o-bromoanisole is synthesized through three steps, anisole is used as raw material, p-sulfonic anisole is first synthesized, 2-bromo-4-sulfonic anisole is synthesized on the basis, and finally, the sulfonic group is removed to obtain o-bromoanisole. Since anisole is used as raw material, the problems of multiple by-products, low yield and low purity existing in the synthesis path of phenol are avoided. Meanwhile, all the raw materials of the application have low cost, the process steps are simple, and etherification is not needed. Meanwhile, since anisole is used as raw material, hydrobromic acid and hydrogen peroxide can be used in the intermediate step, the hydrobromic acid is oxidized to generate bromine, the reaction rate can be controlled, the reaction efficiency is improved, the waste of bromine is reduced, the purity of the prepared product can reach 99.4%, the yield reaches 96.26%, and the product can be applied on a large scale in industry.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg or less of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg or less of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The invention provides various salt forms of deuterated dextromethorphan as shown in a formula (I) as well as a preparation method and application of the various salt forms. The various salt forms comprise tartrate, citrate, hydrobromide and benzoate. Also provided are various crystal forms of the above salts. The salt has excellent effects in the aspects of stability, biological activity, bioavailability, drug effect and the like, and is suitable for development of pharmaceutical preparations.

The present invention provides a salt of a triazine compound which has an inhibitory action against aldosterone synthase and is useful as a drug, and especially as a drug for preventing or treating primary aldosteronism and the like, a crystal thereof, and a method for producing the same. Specifically, the present invention provides a pharmaceutically acceptable salt of 3-[4-[[trans-4-(acetamino)cyclohexyl]carbamoylmethyl]piperazin-1-yl]-5-(p-tolyl)-1,2,4-triazine, wherein the salt is hydrobromide, sulfate, succinate, or tosylate, and the like.

The embodiment of the invention provides a cassiterite high-precision tin isotope determination method which comprises the following steps: selecting a cassiterite sample, grinding, and weighing the ground cassiterite sample; adding the weighed cassiterite sample into a sample dissolving tube, slowly adding high-purity hydrobromic acid into the sample dissolving tube, and heating and sealing the sample dissolving tube to completely dissolve cassiterite; taking out the dissolved sample, and diluting the dissolved sample to a constant volume; sequentially carrying out evaporation acid removal and redissolution on the diluted and constant-volume sample to obtain a sample to be measured; establishing a cup structure for Sn isotope static determination; and performing high-precision Sn isotope measurement on the to-be-measured sample according to the cup structure. According to the method, complete dissolution of cassiterite can be achieved, the extremely high tin recovery rate is ensured, the problem of extra isotope fractionation caused by solution volatilization in the processes of tin recovery incompleteness, dissolution and evaporation drying to medium conversion can be effectively solved, and therefore the accuracy and reliability of Sn isotope analysis are ensured.

The present application relates to a method for increasing the adhesion of a slide, belonging to the technical field of biological medicine, to solve at least one of the problems in the prior art, such as poor adhesion of mycobacterium tuberculosis on the slide, easy to drop the slide in subsequent operation, serious loss of mycobacterium tuberculosis, and influence on the diagnosis rate of pulmonary tuberculosis. The dextromethorphan hydrobromide tablets and the flaxseed gum can generate a high molecular water-soluble polymer with strong positive charge adhesion under the action of a catalyst, that is, the binder described in the present application. Since mycobacterium tuberculosis is the pathogen causing tuberculosis, its surface has a large number of negative charges. Once the mycobacterium tuberculosis with negative charges on the surface contacts the binder containing a large number of positive charges, the surface of the mycobacterium tuberculosis will be quickly wrapped by the binder, forming a firm adhesion layer, and the problem of easy dropping of the slide will not occur during staining and subsequent detection.

The application provides a preparation method of low-impurity vonerogefumate. The application provides a method for removing impurities A-E in the preparation of vonerogefumate, wherein vonerogefumate is reacted with hydrobromic acid to obtain vonerogefumate hydrobromide, and the method specifically comprises the following steps: (1) dissolving vonerogefumate and hydrobromic acid in a solvent; (2) cooling or directly precipitating a solid; and (3) separating to obtain vonerogefumate hydrobromide. The method can remove impurities A-E which are difficult to remove by a recrystallization refining method, and the method has good selectivity for impurities A-E. The application provides an impurity D, a preparation method thereof and application of the impurity D as an impurity control sample of vonerogefumate.

The present invention belongs to the field of medicinal chemistry and relates to a triazine-thiazolidinone compound and its preparation method and application. Its structural formula is wherein R1 is any one of alkyl, pyranyl, indolyl, phenyl or thienyl. Its pharmaceutically acceptable salt is the acid salt of the compound, and the acid is any one of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, boric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, benzenesulfonic acid, citric acid, lactic acid, pyruvic acid, tartaric acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, salicylic acid or phenylacetic acid. The triazine-thiazolidinone compound skeleton provided by the present invention is novel, has a good inhibitory effect on glucose transporter 1 (GLUT1), and its inhibitory effect in HT29 cells is much better than that of positive control compound BAY-876, with good potential for further development as an anti-tumor drug.

The application provides a synthesis method of 6-bromo-2-chloro-3-nitropyridine and relates to the technical field of organic synthesis. 2-amino-3-nitro-6-chloropyridine is reacted with a hydrobromic acid acetic acid solution to obtain 2-amino-3-nitro-6-bromopyridine, which is diazotized to obtain 6-bromo-2-hydroxy-3-nitropyridine, and then the 6-bromo-2-hydroxy-3-nitropyridine is reacted with a chlorinating reagent to obtain 6-bromo-2-chloro-3-nitropyridine. The synthesis method of 6-bromo-2-chloro-3-nitropyridine has the advantages of easy availability of raw materials, low price, mild reaction condition, simple process, high economic benefit, suitability for large-scale production, and the like, can solve the current situation of high price of 6-bromo-2-chloro-3-nitropyridine, and can play a positive role in the promotion of downstream products of 6-bromo-2-chloro-3-nitropyridine.

The invention discloses an analysis method for determining halogenated alkane impurities in tigliptin hydrobromide, and relates to the technical field of quality analysis. In order to solve the problem of detection of halogenated alkane impurities in tigliptin hydrobromide, the invention provides a convenient, efficient and accurate detection method. The method comprises the following steps: preparing a test solution and an impurity reference solution, and detecting by adopting a gas chromatographic method; the method can be used for accurately determining the content of halogenated alkane in tigliptin hydrobromide, plays a guiding role in development of a synthesis process, and contributes to establishment of quality standards of tigliptin hydrobromide bulk drugs.